Radiopharm Theranostics Limited (RADX) Fair Value 2026

RADX · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

2.0 /10

32 fundamental signals · 0 models active

Value Trap Risk

DANGER (80/100)

Quick Summary — As of 2026-08-28, Radiopharm Theranostics Limited (RADX) trades at $2.41. QOC: 2.0/10. Value Trap Risk: 80/100 (DANGER). 0/13 models active.

Key Facts

Ticker
RADX
Price
$2.41
Quality Score
2.0/10
Value Trap Risk
80/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Value Trap score of 80 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give RADX?

0 Intrinsic Value Models vs. Current Price ($2.41)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Radiopharm Theranostics Limited (RADX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Radiopharm Theranostics Limited currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About RADX?

0 of 13 models are currently active for RADX. See which stocks rank higher →

How Does RADX Rank in Biotechnology?

Among 625 Biotechnology stocks, RADX ranks #621 by Quality of Company score. CirclFi's QOC score of 2.0/10 evaluates 32 fundamental signals. A score of 2.0 signals below-average fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a biotech sector, Radiopharm Theranostics Limited operates in a sector where partnership revenue is a critical driver of valuation. Investors evaluating RADX should weigh these sector-specific dynamics alongside our model-derived fair values.

Is RADX a Value Trap?

CirclFi's Value Trap algorithm assigns RADX a score of 80/100 (DANGER). This is a high-risk signal. Deteriorating fundamentals suggest the discount may be justified. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Radiopharm Theranostics Limited. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Radiopharm Theranostics Limited's fundamental quality profile registers 2.0/10. This concerning score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record. Investors should note the company's elevated value trap risk score, which suggests apparent undervaluation may not be what it seems.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every RADX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Radiopharm Theranostics Limited Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

PYPDPolyPid Ltd.QOC 2.0PBMPsyence Biomedical Ltd.QOC 2.0PPBTPurple Biotech LtdQOC 2.1PLRZPolyrizon Ltd.QOC 1.9ANLAdlai Nortye Group Ltd.QOC 2.1MDWDMediWound Ltd.QOC 1.9ATNMActinium Pharmaceuticals, Inc.QOC 6.0IMMXImmix Biopharma, Inc.QOC 5.0ALLRAllarity Therapeutics, Inc.QOC 4.4EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: PYPD · PBM · PPBT · PLRZ · ANL · MDWD · ATNM · IMMX · ALLR · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to RADX?

6 companies across all industries closest to RADX’s Quality of Company score of 2.0/10.

VIVOVivoPower PLCQOC 2.0JXGJX Luxventure Group Inc.QOC 2.0EPSMEpsium Enterprise LimitedQOC 2.0ASMAvino Silver & Gold Mines Ltd.QOC 2.0CRMLCritical Metals Corp.QOC 2.0NVDANVIDIA CorporationQOC 10.0

Read investment analysis: VIVO · JXG · EPSM · ASM · CRML · NVDA

Where Does RADX Sit in CirclFi's Biotechnology Rankings?

RADX is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Radiopharm Theranostics Limited’s Valuation?

What is Radiopharm Theranostics Limited's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Radiopharm Theranostics Limited (RADX). The Quality of Company score is 2.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is RADX overvalued or undervalued right now?

At $2.41, 0 of 0 active models suggest RADX may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Radiopharm Theranostics Limited's business model in Biotechnology.

What does a Quality of Company score of 2.0 mean for RADX?

Radiopharm Theranostics Limited's QOC of 2.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on RADX?

CirclFi analyzes RADX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is RADX a value trap in 2026?

Radiopharm Theranostics Limited's Value Trap score is 80/100 (DANGER). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Radiopharm Theranostics Limited (RADX) a Quality of Company score of 2.0/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/RADX/ · Methodology
Primary sources for this RADX valuation
  • Financial statements: Radiopharm Theranostics Limited 10-K and 10-Q filings on SEC EDGAR (CIK 0001949257) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for RADX as of ; valuations recomputed .